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integral Dose-Based inverse 
Optimization May reduce side effects 
in radiotherapy of Prostate carcinoma
Ivaylo B. Mihaylov*
Department of Radiation Oncology, University of Miami, Miami, FL, USA
Purpose: The purpose of this work is to apply a novel inverse optimization approach, 
based on utilization of quantitative imaging information in the optimization function, to 
prostate carcinoma.
Materials and methods: This new inverse optimization algorithm relies upon 
quantitative information derived from computed tomography (CT) imaging studies. The 
Hounsfield numbers of the CT voxels are converted to physical density, which in turn 
is used to calculate voxel mass and the corresponding integral dose, by summation 
over the product of dose and mass in each dose voxel. This integral dose is used for 
plan optimization through its global minimization. The optimization results are compared 
to the optimization results derived from most commonly used dose–volume-based 
inverse optimization, where objective functions are formed as summation over all dose 
voxels of the squared differences between voxel doses and user specified doses. The 
data from 25 prostate plans were optimized with dose–volume histogram (DVH) and 
integral dose (energy) minimization objective functions. The results obtained with the 
energy- and DVH-based optimization schemes were studied through commonly used 
dosimetric indices (DIs). Statistical equivalence tests were further performed to establish 
population-based significance results.
results: Both DVH- and energy-based plans for each case were normalized so that 95% 
of the planning target volume receives the prescription dose. The average differences for 
the rectum and bladder DIs ranged from 1.6 to 25%, where the energy-based quantities 
were lower. For both femoral heads, the energy-based optimization-derived doses 
were lower on average by 32%. The statistical tests demonstrated that the significant 
differences in the tallied dose indices range from 2.7% to more than 50% for rectum, 
bladder, and femoral heads.
conclusion: For majority of the clinically relevant dosimetric quantities, energy-based 
inverse optimization performs better than the standard of care DVH-based optimization 
in prostate carcinoma. The population averaged statistically significant differences range 
from ~3 to ~50%. Therefore, this newly proposed optimization approach, incorporating 
explicitly quantitative imaging information in the inverse optimization function, holds 
potential for further reduction of complication rates in prostate cancer.
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inTrODUcTiOn
Radical prostatectomy and radiotherapy are both commonly 
used treatment options for clinically localized prostate cancer 
(1). Both treatment approaches have evolved over time, such 
that to maximize cancer-free survival, while minimizing health-
related risks like urinary incontinence, bowel incontinence, and 
sexual dysfunction. However, to date, there is still no superior 
single treatment that is devoid of side effects (1). Three recent 
randomized trials have shown a consistent improvement in 
biochemical failure when adjuvant radiotherapy is administered 
with prostatectomy (2). However, the price to be paid for the 
increased control is the increased risk for complications and side 
effects in the radiotherapy arm by a factor of 2 (3).
Over the past decade, many publications have shown that 
high dose intensity-modulated radiotherapy (IMRT) represents 
optimal form of external beam radiotherapy for localized prostate 
cancer (4). The combination of IMRT with image guidance (5) 
has allowed an enhanced target precision, together with the 
accompanying reduction in clinical target volumes (CTVs) and 
even perhaps reduction in the treatment-related toxicity. Those 
findings suggest that the development and the incorporation into 
clinical practices of novel advanced radiotherapy planning and 
delivery techniques will allow safer radiation delivery for numer-
ous of patients with potentially lower side effects.
Modern radiotherapy treatment planning relies on the 
dose–volume histogram (DVH) paradigm, where doses to 
volumes are employed (6–9). The widespread use of DVHs 
stems from the wealth of clinical information as well as clini-
cian’s experience with dose–volume metric (10). DVHs were 
introduced three decades ago, while IMRT gained widespread 
application a decade later (9, 11–15). At that time, homoge-
neous dose calculations were the norm, with heterogeneous 
dose calculations hardly even possible. In the last two decades, 
however, these shortcomings were overcome, and today, het-
erogeneous dose calculations are the norm in all commercial 
treatment planning systems (TPSs). Despite the use of more 
sophisticated dose calculation algorithms, however, the inverse 
IMRT optimization is still based to a large extent on the DVH 
paradigm which, by its virtue, is homogeneous in nature. In 
other words, all voxels in the irradiated volume are treated by 
the optimization cost function derived only in terms of doses 
and volumes, thereby ignoring the fact that the voxels have 
inhomogeneous content. Notably, the computed tomography 
(CT) imaging data provide voxel density information which 
can be used beyond its application to radiation attenuation 
and absorption (dose deposition). This fact has been pointed 
out in a recent study where novel optimization cost function 
was introduced (16). In this work, the inhomogeneity of the 
voxels was directly incorporated into the cost function, where 
the voxel mass utilization was achieved through integral dose 
(energy-based optimization hereafter).
The purpose of the present work is to investigate the applica-
bility of this novel energy-based optimization scheme to prostate 
cancer. The abdominal region consists of almost uniform density, 
where the dose calculation accuracy will minimally impact the 
obtained optimization solution (17). Thereby, if there are any 
observable differences between contemporary inverse opti-
mization techniques and this newly proposed form of the cost 
function, they will result from the intrinsic properties of this cost 
function itself.
MaTerials anD MeThODs
Patient Data
This study was carried out in accordance with the recommenda-
tions of University of Miami Institutional Review Board (IRB) 
guidelines, with written informed consent from all subjects. All 
subjects gave written informed consent, in accordance with the 
Declaration of Helsinki, as per University of Miami IRB approved 
protocol for this study. The CT data from 25 prostate cancer 
subjects were used in this study. For each case, CTV, including 
only the prostate, and planning target volume (PTV) were con-
toured by the attending physician. The prescription doses ranged 
from 70 to 80 Gy in 2 Gy daily fractions. The PTV was obtained 
from the CTV by a uniform expansion of ~1  cm. In addition, 
rectum, bladder, and femoral heads were outlined as organs at 
risk (OARs) and were used in the IMRT optimization as dose 
limiting structures.
Objective Functions
The objective functions used in the inverse optimization of the 
treatment plans are described below. They are strictly limited to 
the OAR doses, while the target dose objectives were specified in 
terms of minimum, maximum, and uniform doses to the PTV. 
The DVH-based optimization is realized through an objective 
function described by Eq. 1
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where V denotes the volume of interest (VOI), di is the dose in 
voxel (3D volume element) i of the volume V, dj is the desired dose 
in each voxel, and Δvi is the voxel volume (16, 18, 19). The sum-
mation is over the volume for which the dose di is greater than the 
objective dose dj. This equation can also be applied for minimum, 
maximum, and uniform dose objectives, where the summations 
are over the volumes with di smaller than dj, di greater than dj, 
and the entire organ volume, respectively. An optimization func-
tion Fj is created for each optimization objective specified for the 
organ of interest. In the case of DVH-based optimization, more 
than one objective can be specified for an anatomical structure of 
interest. A summation over all objective functions Fj generates a 
composite objective function outlined in Eq. 2
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The normalization of the voxel volume vi with respect to the 
total volume V of the anatomical structure of interest in Eq. 1 is 
needed so that the composite objective function of Eq. 2 can be 
generated. This normalization assures that all of the individual 
OAR Fj are dimensionless, and they can be combined with the 
objective functions for the target(s) (which are also dimension-
less), thereby creating the global objective function from Eq. 2.
FigUre 1 | Flowchart of the optimization process. The left-hand arm 
represents the DVH-based optimization sequence, while the right-hand arm 
outlines the energy-based optimization sequence.
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So far integral dose has only been used to explore the 
properties of treatment plans (20–22). However, it has been 
argued recently that integral dose has some far reaching desir-
able properties, which can be used in radiotherapy inverse plan 
optimization (16). The integral dose represents the total energy 
deposited in a VOI. Therefore, minimizing the integral dose is in 
essence a minimization of the total deposited energy in that VOI. 
The discrete form of the objective function Fj used in this work 
is presented in Eq. 3
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where again V denotes the volume of the anatomical structure of 
interest, di is the dose in voxel i, ρi is the density of the material in 
that voxel, mi is the mass of that material, and vi is the volume of 
the voxel (16). The summation is over all dose voxels contained 
in the volume of the organ of interest V. The physical density ρ 
in each voxel is obtained from the Hounsfield units (HUs) con-
tained in the DICOM CT images. The conversion of the HUs to 
physical density is performed though CT-to-density conversion 
table, which is present in each TPS since it is necessary for the 
dose calculations. The quantity Eobjective in Eq. 3 is the desired inte-
gral dose, which needs to be imparted on the organ of interest. 
This in essence is a normalization term, which ensures that the 
individual objective functions Fj are dimensionless, in analogy 
to the DVH-optimization case (cf. Eq.  1). The normalization 
allows the combination of dimensionless OAR objectives with 
the dimensionless objective functions for the target(s) in Eq. 2. 
For each anatomical structure considered in the optimization, 
there is only one energy-based objective function of the type 
given by Eq. 3.
Both Eqs 1 and 3 have one adjustable parameter each. While in 
Eq. 1, it is the desired dose dj, in Eq. 3, it is the desired integral dose 
Eobjective. The existence of each of those adjustable parameters is a 
prerequisite for the inverse optimization. By planner’s action on 
those parameters during the optimization process, the computer 
optimization algorithm is invoked to change voxel doses di (cf. 
Eqs 1 and 3) during optimization, therefore, causing the solution 
to converge to a point where the global objective function from 
Eq. 2 is minimized (i.e., maximum target doses and minimum 
OAR doses).
Treatment Planning
For each patient, two IMRT plans were created: one based on 
DVH quadratic objective function (9, 18, 19), and another 
one based on energy-minimization objective function (16). 
For the PTV doses, both optimization schemes utilized pure 
dose objective functions, namely, minimum, maximum, and 
uniform doses. For the OARs, the IMRT objectives were DVH 
based and energy based in the two arms, respectively. Figure 1 
outlines a schematic representation of the study flow. In essence, 
this is a multistage trail-and-error optimization scheme. With 
either optimization scheme, there is a full optimization cycle 
performed with only DVH target objectives. After convergence 
of the optimization, DVHs for all OARs are created. From 
those DVHs, the DVH-optimization functions (cf. Eq.  1) are 
evaluated. There are three objectives per OAR for prespecified 
relative volumes of 1, 35, and 70% of the OAR. Objective doses 
dj are varied such that the individual objectives Fj for all OARs 
are about 5% larger than the largest objective value, obtained 
from the target objective functions (usually this is the objective 
value derived from the target dose uniformity objective func-
tion). After the objective doses for the OARs are determined, 
the entire optimization is performed again. At the end of this 
optimization cycle, the doses (and, respectively, the DVHs) of 
the OARs are reduced, while the target dose heterogeneity is 
increased. The OAR objective doses dj are evaluated again as 
described above, namely, until the Fj for all OARs are about 
5% larger than the target objective value for dose homogeneity, 
and the optimization is performed again. Therefore, with each 
adjustment (reduction) of OAR objective doses dj, the dose 
heterogeneity of the PTV dose increases. The process of stepwise 
reduction of OAR objective doses is terminated when at the 
end of the optimization run the SD of the doses across the PTV 
is of the order of 4% of the prescription dose. The obtained 
solution is thereby multistaged trial and error procedure where 
OAR objective doses are lowered through multiple optimization 
runs. The procedure with the integral dose-based optimization 
is identical, with the only difference that there is only one 
objective per OAR, and the variable parameters are not the 
individual doses dj but rather the Eobjective from Eq. 3.
FigUre 2 | Dose–volume histogram (DVh) (left) and isodose plots in three different plains (right) for one case. The DVHs for the planning target volume 
(PTV), rectum, bladder, and femoral heads are presented on the left. The right-hand side outlines the isodoses from 7,200 cGy (prescription dose) to 2,000 cGy in 
1,000 cGy intervals. The axial, the sagittal, and the coronal cuts are through the isocenter, located in the centroid of the PTV.
4
Mihaylov Energy-Based OAR Dose Reduction
Frontiers in Oncology | www.frontiersin.org March 2017 | Volume 7 | Article 27
All IMRT plans were generated with deliverable IMRT 
optimization, where the final optimization solution incor-
porated all machine parameters (17, 23–25). The deliverable 
optimization is more restrictive than the intensity map (only) 
optimization, but the advantage is that the obtained solution 
is clinically viable and can be delivered. Both plans for each 
patient consisted of seven coplanar 6 MV beams. A total of 70 
step-and-shoot IMRT segments were allowed in each plan with 
minimum segment area of 5 cm2 and minimum of 5 monitor 
units (MUs) per segment. If the segment area or the minimum 
allowed MUs are decreased, then the deliverable optimization 
may result in overmodulation where quality assurance checks 
may deem the achieved plans clinically unachievable. Thereby, 
by restricting the degree of intensity modulation plan deliver-
ability is secured. The investigated optimization cost functions 
were interfaced to Pinnacle TPS (Philips Radiation Oncology 
Solutions, Fitchburg, WI, USA) by plugins. This allowed the 
use of Pinnacle’s dose calculation algorithms as well as its direct 
machine parameter optimization module in the generation 
of the deliverable plans. For each patient, the DVH- and the 
energy-based plans were normalized such that 95% of the PTV 
received the prescription dose. The OAR doses were optimized 
until SD of the dose across the PTV in each plan became of the 
order of 4.0% (26).
analyses
DVH optimization is for a large part the standard of care in 
modern radiation therapy. Therefore, the doses derived from 
the DVH optimization were used as a reference standard with 
respect to which the energy-based optimization results were 
evaluated. The performance of each optimization scheme was 
assessed on the basis of commonly used dosimetric indices 
(DIs) (17, 27, 28), since DVH metric is the most commonly 
used tool in the clinical decision making. The tallied DIs were 
dose to 95% of the PTV volume, doses to 15, 25, 40, and 60% 
of rectum and bladder volumes, as well as doses to 10% of 
the volumes of each femoral head. Furthermore, maximum 
PTV doses and dose to 5% of the PTV volume were also 
interrogated.
Statistical equivalence tests were used to determine the 
minimum dose interval, such that the reference and the com-
pared quantities were deemed statistically equivalent. The tests 
were performed for each tallied index using two-tailed paired 
t-tests for p-values of less than 5% (17, 29). The procedure for 
the statistical tests is as follows. Absolute doses for each DI were 
extracted for each optimization scheme. Next, dose equivalency 
interval was initially set to zero and the t- and p-values com-
puted for the observed absolute dosimetric differences between 
the two optimization schemes for each DI. Subsequently, the 
dose interval was progressively increased in 1  cGy steps until 
equivalence between the indices was reached (namely, until p 
became larger than 0.05). In essence, the dose equivalence inter-
val indicates when the two solutions are indistinguishable from 
statistical point of view. Larger the paired (on patient-by-patient 
basis) absolute dose differences between the DIs, the larger the 
equivalence interval, the larger the statistical significance level 
and vice versa.
resUlTs
Figure  2 outlines DVH and isodose comparisons for one case 
from the cohort. The color-coded DVHs are presented on the left-
hand side, while the isodose distributions are presented on the 
right-hand side. The solid DVHs resulted from the dose distribu-
tion derived from the DVH-based optimization, while the dashed 
DVHs resulted from the energy-based dose distribution. In this 
particular case, for equivalent PTV coverage (doses are normal-
ized such that 95% of the PTV receives 7,200  cGy with either 
optimization), the energy-based optimization results in very 
similar bladder DVH as compared to DVH-based optimization. 
FigUre 3 | comparison of all normalized dose indices for the organs 
at risk (Oars). Details on the index normalization are presented in the text. 
The top, middle, and bottom panels outline the results for all tallied OAR 
doses for bladder, rectum, and femoral heads, respectively.
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However, the rectum and the femoral head DVHs are noticeably 
lower with energy-based inverse optimization. The screen cap-
tures on the right-hand side show the DVH-derived (left) and the 
energy-derived (right) isodoses. As can be noted form these plots, 
there is somewhat larger “spillage” of low doses (orange, magenta, 
and cyan) with DVH-based optimization. This difference in the 
lower dose region is also evident from the DVH overlay on the 
left-hand side of the figure.
comparison of Dose indices
The comparisons of all tallied dose indices are presented in 
Figure 3. The quantities obtained from the DVH-optimized plans 
were used as a reference in this normalization, since DVH-based 
optimization is modern day standard of care. The normalization 
of the DIs allows the use of a common scale for all patients since 
the absolute DIs vary from patient to patient due to prescription 
doses, optimization convergence, and patient anatomy (17, 30). 
In order to further aid the comparisons, one is plotted on the 
figure by a dashed line. If a normalized DI is greater than 1 then 
the DVH optimization results in lower absolute value for that 
quantity and vice  versa. When a normalized DI is 1, then the 
DVH- and energy-derived values for that DI are equal. Since the 
prescription for each patient was performed to 95% of the PTV, 
those doses were identical to within 1% and are not presented. 
The top panel of the figure presents the normalized maximum 
dose and does to 5% of the PTV (see legend). In extreme cases, 
the differences range from −7% (i.e., less than 1) to +5% (greater 
than 1), but for the majority of the cases, they are within couple 
percent of each other. Most of DIs for rectum, bladder, and femo-
ral heads demonstrate that energy-based OAR doses are lower 
than the DVH-based OAR doses. The top two panels of the figure 
show that for rectum and bladder, the sparing, achievable with 
energy-based optimization, increases as the fractional volume of 
the OAR increases. The average dosimetric differences between 
the optimization schemes in bladder for instance are 1.9, 5.9, 
17.1, and 21.2% (lower energy-derived values) for 15, 25, 40, and 
60% respectively of bladder volumes. The trend for the rectum is 
identical, namely, the differences become larger as the fractional 
VOI becomes larger. This behavior is to be expected since the 
goal of either optimization is to spare as much as possible the 
OARs after adequate target coverage (namely, 95% of the PTV is 
covered by 100% of the prescription dose) are achieved. Rectum 
and bladder are in direct proximity to the PTV, and thereby, small 
fractions of those anatomical structures could receive doses as 
high as the prescription dose. Therefore, the dose differences 
for small volumes of those anatomical structures are relatively 
small. The bottom panel of Figure 3 shows that the sparing of 
the femoral heads with energy-based optimization is far superior 
than the sparing with DVH-based optimization. In only 2 out of 
50 tallied DIs for the femoral heads, the normalized values are 
at or above 1 (patients 16 and 18, left and right femoral heads, 
respectively).
In addition to the commonly used dose indices described 
above, integral doses were also compared. The entire irradiated 
volume was delineated. The PTV for each patient was subtracted 
from this irradiated volume, and the integral doses for each opti-
mization scheme were calculated for each optimization scheme. 
The normalized (with respect to the DVH-optimization results) 
integral doses are plotted on the top panel of the figure. As it is 
clear from the plot, all integral doses for the energy-based optimi-
zation are lower, which is in contract to the DIs, where not in all 
cases the energy-derived DIs were better than the DVH-derived 
DIs. The integral doses to the irradiated volume were on average 
lower with energy-based optimization by 8%.
statistical analyses
The results of the statistical significance tests are presented in 
Table 1. In the first column, a description of the tallied quantity is 
given. In the second column of the table, the corresponding aver-
age value derived from the DVH-optimized plans is presented. 
For instance, the dose of 6,742 cGy is the average dose to 15% of 
the bladder volume over all 25 cases, derived from DVH-based 
plans. Third column contains the interval (in absolute dose units) 
for which statistical equivalence at p < 5% level is achieved. The 
last column of the table is the ratio between the numbers from 
third and second columns, therefore, indicating the percent 
statistically significant difference between the two optimization 
schemes. Note that in the high dose regions for the rectum and 
bladder, the statistically significant difference is only about 3%, 
while with increasing volume, the statistically significant differ-
ences increase to about ~30%, which is consistent with the data 
TaBle 1 | intervals for which statistical equivalence tests indicate that 
the differences between DVh- and energy-derived dose indices are 
statistically significant (p < 0.05).
index average value 
of tallied index 
derived from DVh 
optimization (cgy)
statistical 
equivalence 
interval (cgy)
change for 
equivalency 
(sparing) 
(%)
Bladder DI15% 6,742 185 2.7
Bladder DI25% 5,861 377 6.4
Bladder DI40% 4,086 696 17.0
Bladder DI60% 2,619 692 26.4
Rectum DI15% 6,603 198 3.00
Rectum DI25% 5,861 402 6.9
Rectum DI40% 4,233 792 18.7
Rectum DI60% 2,763 953 34.5
Rt femoral head DI10% 1,091 553 50.7
Lt femoral head DI10% 1,059 579 54.7
Planning target volume 
DI5%
8,297 62 0.7
Dmax 8,505 90 1.1
The average quantities in column two are derived from the standard (DVH-based 
optimization).
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presented in Figure  3. The statistically significant differences 
to 10% of the volumes of the femoral heads are in excess of 
50%. These findings are exemplified on the DVHs presented in 
Figure 2. For that particular patient, the bladder doses are not 
much different, but the rectal doses show how with decreasing 
dose the DVH resulting from the energy optimization is lower 
than the DVH derived from the DVH-optimized plan. While 
the differences in maximum doses and doses to 5% of the PTV 
range from −7 to +5% (cf. top panel of Figure 3), the statistical 
equivalence tests indicate that over the patient cohort those dif-
ferences are significant at ~1% level as indicated by the last two 
rows in Table 1.
DiscUssiOn
Prostate region is considered to be rather homogenous. In real-
ity, however, this is not the case. Density varies by 5 to 10% over 
the rectum and bladder on average. In the case of the femoral 
heads, the differences are even more dramatic and can as high 
as 50%. Therefore, exploiting the density variation through 
energy-based inverse optimization turns out to be advantageous 
with respect to dose–volume-based optimization as in the DVH 
case. It has been shown in prior studies that when different 
dose calculation algorithms are used the density differences 
may affect the convergence of the optimization solution where 
differences close to 10% have been observed (17). Therefore, the 
use of voxel mass explicitly in the optimization objectives is a 
logical step in the study and the evolution of the optimization 
objective functions.
As it was noted above, DVH optimization usually requires 
several objectives for each OAR, while energy-based optimiza-
tion utilizes a single objective per OAR. This may be particularly 
relevant to serial structures where usually maximum doses 
are of primary concern. The availability of several objective 
functions for a single OAR (DVH case) allows more flexibility 
in shaping maximum dose than in the case with only one 
available objective function (energy case). There are several 
potential solutions which can be utilized for amelioration of 
this deficiency of the energy-based approach. One possibil-
ity would be to specify an additional (to the energy based) 
objective for each serial structure where the point maximum 
dose to the OAR is limited. Alternative option would be to 
use a DVH-based objective for the OAR, where the dose to a 
small fraction of the volume (i.e., 1%) is minimized. A third 
option would be to introduce an additional objective function, 
which is based on modification of Eq. 3. This modification will 
minimize integral dose only for voxels that have doses above 
certain user-defined threshold.
To our knowledge, integral dose has not been related to 
normal tissue complications. Dose–volume parameters, how-
ever, are well known to clinicians because of the vast clinical 
experience, which has been gathered since the introduction of 
DVHs (9, 12). Therefore, integral dose cannot solely be used 
for radiotherapy plan evaluation. Energy-based optimization 
appears to be a useful alternative for inverse optimization, 
while the clinical guidelines and clinical trial protocols in 
terms of established DVH metrics and guidelines should be 
followed.
Another comparison performed in this investigation was 
between the MUs, the integral doses, and the surface (skin) 
doses resulting from each optimization scheme. The average, 
minimum, and maximum MUs derived from the DVH plans 
were 752.7, 505, and 1,026, respectively. In comparison, the 
quantities resulting from the energy-based plans were 760.3, 
547, and 1,011  MUs, respectively. The energy-based plans 
resulted in slightly higher average MUs over the patient cohort, 
but that difference was small (about 1%). Integral doses within 
the entire irradiated volume were calculated for each patient and 
each optimization approach. In all cases without exception, the 
integral dose derived from the energy-based plan was lower than 
the integral dose derived from the DVH plans. The differences 
ranged from 0.1 to 3.1%, with average difference of 1%. As it 
was mentioned above, there is no evidence in the literature what 
the effect of those integral dose differences might be. Finally, in 
order to estimate the surface doses, a 0.3 cm layer was outlined 
on the patient surface, representing patient’s skin. The maximum 
and average skin doses were calculated on patient-by-patient 
basis. The differences in maximum doses ranged from −12.8% 
(lower skin dose with energy-based optimization) to +12.1% 
(higher skin dose with energy-based optimization), with aver-
age difference of −0.4%. For average skin doses, the minimum, 
maximum, and average differences were −16, 5.7, and −7%, 
respectively. These findings indicate that energy-based optimi-
zation delivers slightly lower dose to skin. However, only in four 
cases, the actual skin dose was over 3,000 cGy (and only in two 
cases around 3,500 cGy). Even in these extreme scenarios, the 
maximum skin dose is about 100 cGy per day over the course 
of treatment. The calculations do not account for patient daily 
repositioning, which will smear out the maximum dose some-
what, thereby decreasing it. Furthermore, if the skin dose is of 
a concern, the number of beams may be increased, therefore, 
spreading out the entrance dose, which would decrease the skin 
dose further.
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cOnclUsiOn
The results of this study presented herein indicate that this novel 
inverse optimization framework, based on the exploration of 
quantitative imaging information derived from the CT data, is 
capable of improving normal tissue sparing when compared 
to the standard of care. The observed statistically significant 
differences range from about 3% in the high dose regions 
to more than 50% in the low dose regions. It is interesting 
to note that this normal tissue sparing is observed in rather 
homogenous media, characteristic for the prostate popula-
tion. With DVH-based optimization, the cost function is a 
quadratic function of dose differences multiplied by volume, 
while the objective function in energy-based optimization is a 
product of dose and mass. The observations presented above 
imply that the minimization of the integral dose allows better 
normal tissue sparing than DVH-based inverse optimization 
even in almost homogenous media such as the pelvic region. 
Since both optimization schemes use the same dose calculation 
algorithm and the variations in tissue density are relatively small, 
it can be concluded that the obtained results are property of 
the underlying optimization cost function. This cost function 
represents a further evolution of our strive for personalized 
medicine, where therapy is tailored to specific patient anatomi-
cal information, and now tissue density representation. By its 
virtue, high-energy ionizing radiation destroys human tissue. 
Thereby, minimizing radiation doses to healthy tissue is one of 
the primary goals of modern radiotherapy treatment planning 
and delivery. The main findings in this work strongly suggest 
that energy minimization-based inverse optimization holds the 
potential to reduce further toxicity in radiotherapy treatment 
of one of the most common cancers.
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